Details of the Drug

General Information of Drug (ID: DM3FS1G)

Drug Name

RT-001

Synonyms

RT-001, Revance therapeutics; BoNTA protein (topical gel, hyperhidrosis), Revance

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Phase 2	[1]
Friedreich's ataxia	8A03.10	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

310.5

Logarithm of the Partition Coefficient (xlogp)

7.3

Rotatable Bond Count (rotbonds)

16

Hydrogen Bond Donor Count (hbonddonor)

0

Hydrogen Bond Acceptor Count (hbondacc)

2

Chemical Identifiers

Formula: C20H36O2
IUPAC Name: ethyl (9Z,12Z)-11,11-dideuteriooctadeca-9,12-dienoate
Canonical SMILES: [2H]C([2H])(/C=C\\CCCCC)/C=C\\CCCCCCCC(=O)OCC
InChI: InChI=1S/C20H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h8-9,11-12H,3-7,10,13-19H2,1-2H3/b9-8-,12-11-/i10D2
InChIKey: FMMOOAYVCKXGMF-XMCVDNGOSA-N

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Botulinum toxin A (Bact botA)	TTB52WU	BXA1_CLOBO	Modulator	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01124565) Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of Revance Therapeutics.